Evidence map›Paper›PMID 33003322›Full record

ArticlePharmaceutics2020

Self-Assembled Cationic-Covered Nanoemulsion as A Novel Biocompatible Immunoadjuvant for Antiserum Production Against

Arthur Sérgio Avelino de Medeiros, Manoela Torres-Rêgo, Ariane Ferreira Lacerda, Hugo Alexandre Oliveira Rocha, Eryvaldo Sócrates Tabosa do Egito, Alianda Maira Cornélio, Denise V Tambourgi, Matheus de Freitas Fernandes-Pedrosa, Arnóbio Antônio da Silva-Júnior

Abstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arthur Sérgio Avelino de MedeirosLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.ORCID 0000-0002-2863-9610
Manoela Torres-RêgoLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.ORCID 0000-0002-8535-1533
Ariane Ferreira LacerdaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.
Hugo Alexandre Oliveira RochaDepartment of Biochemistry, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.ORCID 0000-0003-2252-1221
Eryvaldo Sócrates Tabosa do EgitoLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.ORCID 0000-0002-2180-3991
Alianda Maira CornélioDepartment of Morphology, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.ORCID 0000-0001-5762-2538
Denise V TambourgiLaboratory of Immunochemistry, Butantan Institute, Av. Vital Brasil, 1500, São Paulo 05503-900, Brazil.ORCID 0000-0003-1896-9074
Matheus de Freitas Fernandes-PedrosaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.
Arnóbio Antônio da Silva-JúniorLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59010-180, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 308382/2017-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 436051/2018-4Coordenação de Aperfeiçoamento de Pessoal de Nível Superior PNPD 23038.007487/2011-91, Financial code 001
6 · The paper itself

Abstract

This study assesses the efficacy of different nanoemulsion formulations as new and innovative adjuvants for improving the in vivo immunization against the

Indexed as

immunoadjuvantliquid crystalnanoemulsion adjuvantphase transitionsurface functionalizationTityus serrulatus antiserum

Identifiers

PMID33003322
PMCPMC7599857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.